Silexion Therapeutics Announces Preclinical Data Showing SIL204 Upregulated FAS And Downregulated HLA-G Across Three KRAS-Mutant Pancreatic And NSCLC Cell Lines

Loading news article.

Silexion Therapeutics Announces Preclinical Data Showing SIL204 Upregulated FAS And Downregulated HLA-G Across Three KRAS-Mutant Pancreatic And NSCLC Cell Lines | WAPE

Silexion Therapeutics Announces Preclinical Data Showing SIL204 Upregulated FAS And Downregulated HLA-G Across Three KRAS-Mutant Pancreatic And NSCLC Cell Lines

Article summary

Related companies

Comments —